8.07Open8.07Pre Close0 Volume13 Open Interest12.50Strike Price0.00Turnover324.01%IV-1.01%PremiumDec 20, 2024Expiry Date8.28Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9037Delta0.0172Gamma2.35Leverage Ratio-0.1073Theta0.0022Rho2.12Eff Leverage0.0052Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet